Overview

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.